Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MGRX
MGRX logo

MGRX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.405
Open
0.367
VWAP
0.39
Vol
664.44K
Mkt Cap
6.40M
Low
0.361
Amount
257.07K
EV/EBITDA(TTM)
--
Total Shares
16.29M
EV
5.53M
EV/OCF(TTM)
--
P/S(TTM)
5.91
Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.
Show More

Events Timeline

(ET)
2026-01-13
17:40:00
Mangoceuticals Files to Sell 2.64M Shares of Common Stock
select
2025-12-19 (ET)
2025-12-19
07:40:00
Mangoceuticals Partners with Cube Group for Up to $100M Solana Digital Asset Strategy
select
2025-12-18 (ET)
2025-12-18
08:40:00
Mangoceuticals Signs $2.5M Direct Offering Agreement
select
2025-11-13 (ET)
2025-11-13
14:33:09
Novo refutes collaboration with Mangoceuticals regarding obesity medication, according to Reuters.
select
link
2025-11-13
14:28:41
Eli Lilly Declares No Connection to Mangoceuticals
select
link
2025-11-13
07:24:32
Mangoceuticals Collaborates with Eli Lilly and Novo to Offer Zepbound and Wegovy Access
select
2025-05-27 (ET)
2025-05-27
09:11:03
Mangoceuticals shares results from field studies on MGX-0024
select
2025-04-25 (ET)
2025-04-25
09:02:23
Mangoceuticals enters into agreement to acquire assets of Smokeless Technology
select
2025-03-25 (ET)
2025-03-25
09:07:57
Mangoceuticals enters master distribution agreement for Diabetinol rights
select

News

Newsfilter
8.5
03-06Newsfilter
Mangoceuticals Files for Global Patent Protection on Antiviral Additive
  • Global Patent Filing: Mangoceuticals filed a PCT international application on February 26, 2026, to secure global patent protection for its antiviral animal feed and drinking water additive technology MGX-0024, demonstrating the company's proactive approach in innovative health solutions.
  • Clinical Trial Results: MGX-0024 achieved zero respiratory-related mortality across 29,000 birds in commercial field trials and showed statistically significant prophylactic benefits against highly pathogenic H5N1 in the ICAR-NIHSAD controlled challenge study, further solidifying its market competitiveness.
  • Intellectual Property Expansion: The PCT application enables the company to pursue patent protection in over 150 countries through a streamlined process, indicating its strategic intent in global markets, particularly the commercialization potential in key markets like India.
  • Current Technology Protection: MGX-0024 is protected in the U.S. under Patent No. 11,517,523, with corresponding national patents granted or pending in the EU, Canada, China, India, Australia, and Japan, ensuring comprehensive global coverage of its technology.
Benzinga
8.5
02-20Benzinga
Mangoceuticals Stock Surges 42.12% Amid TRT Sales Growth
  • TRT Sales Surge: Since its mid-December launch, Mangoceuticals' injectable testosterone replacement therapy (TRT) sales have skyrocketed by 336% month-over-month, while customer acquisition costs have decreased by 54%, indicating strong market demand and effective cost management.
  • Significant Market Potential: The company anticipates that TRT will be the primary growth driver as MangoRx expands both injectable and oral options, including the PRIME capsule powered by Kyzatrex, further enhancing its market share.
  • Telehealth Platform Advantage: CEO Jacob Cohen highlighted that early demand underscores the value of the firm's telehealth-first approach to men's hormone care, aiming to improve marketing efficiency to meet the growing TRT market demand.
  • Strong Stock Performance: As of Friday, Mangoceuticals shares surged 42.12% to $0.51, nearing its 52-week low of $0.34, reflecting investor optimism about the company's future growth potential.
Benzinga
4.5
02-20Benzinga
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
  • Nasdaq Performance: The Nasdaq Composite rose over 200 points on Friday, closing at 22,917.24, indicating strong demand for tech stocks and potentially reflecting investor optimism about future economic recovery.
  • PPL Corporation Earnings: PPL Corporation reported mixed Q4 fiscal 2025 results with operating revenue of $2.27 billion, falling short of the $2.42 billion consensus estimate, although adjusted EPS of 41 cents met analyst expectations, highlighting challenges in revenue growth.
  • Dividend Increase: PPL raised its quarterly dividend by 4.6% to 28.50 cents per share, demonstrating confidence in future cash flows and a commitment to shareholder returns amidst fluctuating earnings.
  • Market Dynamics: On Friday, communication services stocks gained 2.3%, while healthcare stocks fell by 0.7%, indicating performance disparities across sectors that may influence investors' asset allocation strategies.
Benzinga
4.5
02-20Benzinga
U.S. Stocks Rise in Morning Trade Amid Slowing Economic Growth
  • Market Performance: U.S. stocks rose in morning trading on Friday, with the Dow Jones gaining over 100 points, up 0.24% to 49,516.12, indicating a moderate optimistic sentiment in the market.
  • Economic Slowdown: The U.S. economy grew at an annualized rate of 1.4% in Q4, the lowest since Q1 2025 and significantly below the market estimate of 3%, which may impact investor confidence moving forward.
  • Sector Performance Divergence: Communication services shares rose by 1.7% on Friday, while energy stocks fell by 0.4%, reflecting varied market reactions across sectors that could influence capital flows.
  • Commodity Market Dynamics: Oil prices dipped 0.1% to $66.42, while gold increased by 1% to $5,045.10, indicating that investors are seeking safe-haven assets amid economic uncertainty.
Benzinga
8.5
02-20Benzinga
Mangoceuticals Stock Rises After Successful Launch of TRT Program
  • Significant Sales Growth: Since its launch in mid-December, Mangoceuticals' injectable Testosterone Replacement Therapy (TRT) program has seen a 336% month-over-month sales increase, indicating strong market demand and solidifying the company's position in men's hormone health.
  • Reduced Customer Acquisition Costs: The company reported a 54% decrease in customer acquisition costs during the same period, demonstrating the effectiveness of its $99 subscription model, which enhances overall profitability and market competitiveness.
  • Clear Strategic Focus: CEO Jacob Cohen emphasized that initial customer demand and sales acceleration validate the strategic value of the company's approach to men's hormone health, with injectable and oral formulations expected to drive future growth.
  • Strong Stock Performance: As of now, Mangoceuticals shares have surged 56.16% to 56 cents, reflecting investor confidence in the company's new therapy and optimism about its market prospects.
Benzinga
9.5
02-20Benzinga
Comfort Systems Reports Strong Earnings Beat
  • Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
  • Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
  • Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
  • Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.

Valuation Metrics

The current forward P/E ratio for Mangoceuticals Inc (MGRX.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Mangoceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

penny stocks positive most active today
Intellectia · 167 candidates
Price: $0.10 - $5.00Volume: >= 500,000Price Change Pct: >= $0.10
Ticker
Name
Market Cap$
top bottom
DXST logo
DXST
Decent Holding Inc
12.71M
PRSO logo
PRSO
Peraso Inc
18.93M
MOBX logo
MOBX
MOBIX LABS, INC.
107.20M
TPET logo
TPET
Trio Petroleum Corp
23.74M
EONR logo
EONR
EON Resources Inc
33.48M
SYNX logo
SYNX
Silynxcom Ltd
10.48M
bullish stock today
Intellectia · 51 candidates
Region: USRsi Category: moderatePrice Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
MGRX logo
MGRX
Mangoceuticals Inc
8.63M
AXTI logo
AXTI
AXT Inc
1.64B
GFAI logo
GFAI
Guardforce AI Co Ltd
11.66M
TROO logo
TROO
TROOPS Inc
482.53M
INSG logo
INSG
Inseego Corp
205.17M
RYI logo
RYI
Ryerson Holding Corp
1.44B

Whales Holding MGRX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Mangoceuticals Inc (MGRX) stock price today?

The current price of MGRX is 0.3932 USD — it has increased 2.34

What is Mangoceuticals Inc (MGRX)'s business?

Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.

What is the price predicton of MGRX Stock?

Wall Street analysts forecast MGRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mangoceuticals Inc (MGRX)'s revenue for the last quarter?

Mangoceuticals Inc revenue for the last quarter amounts to 84.25K USD, decreased -36.83

What is Mangoceuticals Inc (MGRX)'s earnings per share (EPS) for the last quarter?

Mangoceuticals Inc. EPS for the last quarter amounts to -0.69 USD, decreased -95.35

How many employees does Mangoceuticals Inc (MGRX). have?

Mangoceuticals Inc (MGRX) has 0 emplpoyees as of March 13 2026.

What is Mangoceuticals Inc (MGRX) market cap?

Today MGRX has the market capitalization of 6.40M USD.